NYSE
$138.44▼ 0.50%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.78BShares out 41.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 6d agoPre-market26.10.19 22:068-KKey event#●●●#●●●#●●●
Veradermics, IncBullish
Veradermics announced that its Phase 3 clinical trial (Study 304) for the hair loss treatment candidate 'VDPHL01' met all primary and secondary endpoints with high statistical significance. In the study of 536 male participants, VDPHL01 demonstrated superior hair growth compared to placebo and a favorable safety profile, supporting the company's path toward potential FDA approval.…more
$138.44-0.50%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Regular26.10.14 02:37SCHEDULE 13GOwnership
Veradermics, Inc
JPMorgan Chase & Co. has filed a Schedule 13G, reporting a beneficial ownership of more than 5% in Veradermics, Inc. This filing serves as an official disclosure of the institution's equity position in the company.…more
$138.44-0.50%vs prev closeView filingShare - 9.3After-hours26.09.04 05:354Ownership
Veradermics, Inc
David Hollander, an insider of Veradermics, Inc., filed a Form 4 statement of changes in beneficial ownership of securities on September 1, 2026. This filing serves as an official report to the SEC regarding the insider's change in shareholdings.…more
$138.44-0.50%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoRegular26.10.20 02:27Bullish#●●●#●●●#●●●
Veradermics Reports Positive Phase 3 Results for Hair Loss Drug
Veradermics announced that its experimental oral hair loss medication, VDPHL01, met all primary and secondary endpoints in a Phase 3 trial. The company plans to use these positive results to support a future FDA approval application.…more
$138.44-0.50%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 6d agoPre-market26.10.19 20:13
●●●●●●●● ●●●●● ●●●●●●
Veradermics' oral hair loss treatment, VDPHL01, met all primary and secondary endpoints in its Phase 3 clinical trial, demonstrating significant hair growth. These positive results support the company's path toward potential FDA approval for the treatment of pattern hair loss.…more
$138.44-0.50%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report